Drug Type Bispecific antibody |
Synonyms Anti CD38 anti ICAM1 bsAb - Virtuoso Therapeutics, Anti-CD38 X anti-ICAM-1 bsAb - Virtuoso Therapeutics, Anti-CD38 anti-ICAM1 bispecific antibody - Virtuoso Therapeutics + [4] |
Target |
Mechanism CD38 inhibitors(Lymphocyte differentiation antigen CD38 inhibitors), ICAM-1 inhibitors(Intercellular adhesion molecule-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | US | 23 Mar 2022 |